Balovaptan + Placebo
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Autism Spectrum Disorder
Conditions
Autism Spectrum Disorder
Trial Timeline
Aug 8, 2018 → Jul 1, 2020
NCT ID
NCT03504917About Balovaptan + Placebo
Balovaptan + Placebo is a phase 3 stage product being developed by Roche for Autism Spectrum Disorder. The current trial status is terminated. This product is registered under clinical trial identifier NCT03504917. Target conditions include Autism Spectrum Disorder.
What happened to similar drugs?
0 of 9 similar drugs in Autism Spectrum Disorder were approved
Approved (0) Terminated (1) Active (8)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05401565 | Phase 2 | Completed |
| NCT05399550 | Phase 2 | Withdrawn |
| NCT03504917 | Phase 3 | Terminated |
Competing Products
20 competing products in Autism Spectrum Disorder